Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1, Open-Label, 10 Day Safety Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females ≥ 18 and ≤ 65 years of age with no clinically significant abnormalities identified by a detailed medical history~* Female subjects must be nonpregnant, nonlactating, and either postmenopausal for at least 2 years, surgically sterile for at least 90 days, abstinent, or agree to use contraception from 1 week prior to Day -1 until 30 days after leaving the study center.~* Male subjects must be surgically sterile, abstinent, or agree to use contraception from Day -1 until 30 days after leaving the study center~* BMI ≥ 18.0 kg/m2 and ≤ 35.0 kg/m2~Exclusion Criteria:~* Hypersensitivity to oxazolidinones or any component in the formulation~* History or current significant ophthalmologic or neurologic condition that would adversely affect the clinical assessments or confound the interpretation of the data (e.g., dense cataracts, macular degeneration, retinitis pigmentosa)~* Positive hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus antibody test result~* Known genetic condition related to mitochondrial disease or dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- TR-701 FA (Type: EXPERIMENTAL): TR-701 FA 200 mg oral once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).